ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: ABT-122

First Posted Date: 2015-05-05

Last Posted Date: 2017-07-24

Lead Sponsor: AbbVie

Target Recruit Count: 158

Registration Number: NCT02433340

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Phase 2

Terminated

Conditions: Psoriatic Arthritis

Interventions: Drug: ABT-122

First Posted Date: 2015-04-29

Last Posted Date: 2016-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 168

Registration Number: NCT02429895

Locations: 🇧🇬
Site Reference ID/Investigator# 138926, Plovdiv, Bulgaria
🇵🇱
Site Reference ID/Investigator# 139000, Bialystok, Poland
🇧🇬
Site Reference ID/Investigator# 138928, Sofia, Bulgaria

and more 33 locations

Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])

Completed

Conditions: Psoriatic Arthritis

First Posted Date: 2015-04-13

Last Posted Date: 2018-10-16

Lead Sponsor: AbbVie

Target Recruit Count: 148

Registration Number: NCT02414633

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer Stage III

Interventions: Drug: Paclitaxel
Drug: Placebo for Veliparib
Drug: Carboplatin
Drug: Veliparib
Radiation: Radiotherapy

First Posted Date: 2015-04-09

Last Posted Date: 2020-07-22

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT02412371

Locations: 🇺🇸
Rhode Island Hospital /ID# 133493, Providence, Rhode Island, United States
🇺🇸
Univ Maryland School Medicine /ID# 132944, Baltimore, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 133494, Boston, Massachusetts, United States

and more 9 locations

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV Infection Genotype 1)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir, dasabuvir
Drug: sofosbuvir (SOF)
Drug: ribavirin (RBV)

First Posted Date: 2015-03-26

Last Posted Date: 2016-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02399345

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)
Multiple Myeloma
Non-Hodgkins Lymphoma
Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Small Cell Lung Cancer
Breast Cancer

Interventions: Drug: ABBV-075
Drug: Venetoclax

First Posted Date: 2015-03-18

Last Posted Date: 2019-11-29

Lead Sponsor: AbbVie

Target Recruit Count: 128

Registration Number: NCT02391480

Locations: 🇺🇸
City of Hope /ID# 154053, Duarte, California, United States
🇺🇸
UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States
🇺🇸
Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States

and more 7 locations

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Phase 2

Completed

Conditions: Erosive Hand Osteoarthritis

Interventions: Biological: ABT-981
Biological: Placebo for ABT-981

First Posted Date: 2015-03-10

Last Posted Date: 2017-08-11

Lead Sponsor: AbbVie

Target Recruit Count: 132

Registration Number: NCT02384538

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

Completed

Conditions: Parkinson's Disease (PD)

First Posted Date: 2015-03-06

Last Posted Date: 2020-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 136

Registration Number: NCT02381444

Locations: 🇩🇪
Gertrudis-Klinik /ID# 144631, Leun-biskirchen, Germany
🇩🇪
Klinikum Altenburger Land /ID# 139643, Altenburg, Germany
🇩🇪
Klinik Haag /ID# 137458, Haag, Germany

and more 24 locations

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: ABT-494
Drug: Placebo

First Posted Date: 2015-02-19

Last Posted Date: 2023-12-27

Lead Sponsor: AbbVie

Target Recruit Count: 220

Registration Number: NCT02365649

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Phase 1

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Colorectal Carcinoma
Glioblastoma Multiforme

Interventions: Drug: ABBV-221

First Posted Date: 2015-02-19

Last Posted Date: 2018-03-30

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02365662

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸
Fundacion Jimenez Diaz, Madrid, Spain

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy